Literature DB >> 21528923

Enhanced intracellular delivery and chemotherapy for glioma rats by transferrin-conjugated biodegradable polymersomes loaded with doxorubicin.

Zhiqing Pang1, Huile Gao, Yuan Yu, Liangran Guo, Jun Chen, Shuaiqi Pan, Jinfeng Ren, Ziyi Wen, Xinguo Jiang.   

Abstract

A brain drug delivery system for glioma chemotherapy based on transferrin-conjugated biodegradable polymersomes, Tf-PO-DOX, was made and evaluated with doxorubicin (DOX) as a model drug. Biodegradable polymersomes (PO) loaded with doxorubicin (DOX) were prepared by the nanoprecipitation method (PO-DOX) and then conjugated with transferrin (Tf) to yield Tf-PO-DOX with an average diameter of 107 nm and surface Tf molecule number per polymersome of approximately 35. Compared with PO-DOX and free DOX, Tf-PO-DOX demonstrated the strongest cytotoxicity against C6 glioma cells and the greatest intracellular delivery. It was shown in pharmacokinetic and brain distribution experiments that Tf-PO significantly enhanced brain delivery of DOX, especially the delivery of DOX into brain tumor cells. Pharmacodynamics results revealed a significant reduction of tumor volume and a significant increase of median survival time in the group of Tf-PO-DOX compared with those in saline control animals, animals treated with PO-DOX, and free DOX solution. By terminal deoxynucleotidyl transferase-mediated dUTP nick-end-labeling, Tf-PO-DOX could extensively make tumor cell apoptosis. These results indicated that Tf-PO-DOX could significantly enhance the intracellular delivery of DOX in glioma and the chemotherapeutic effect of DOX for glioma rats.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21528923     DOI: 10.1021/bc200062q

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  27 in total

Review 1.  Strategies to target drugs to gliomas and CNS metastases of solid tumors.

Authors:  B Milojkovic Kerklaan; O van Tellingen; A D R Huitema; J H Beijnen; W Boogerd; J H M Schellens; D Brandsma
Journal:  J Neurol       Date:  2015-10-17       Impact factor: 4.849

Review 2.  Crossing the Blood-Brain Barrier: Recent Advances in Drug Delivery to the Brain.

Authors:  Mayur M Patel; Bhoomika M Patel
Journal:  CNS Drugs       Date:  2017-02       Impact factor: 5.749

3.  iRGD peptide conjugation potentiates intraperitoneal tumor delivery of paclitaxel with polymersomes.

Authors:  Lorena Simón-Gracia; Hedi Hunt; Pablo Scodeller; Jens Gaitzsch; Venkata Ramana Kotamraju; Kazuki N Sugahara; Olav Tammik; Erkki Ruoslahti; Giuseppe Battaglia; Tambet Teesalu
Journal:  Biomaterials       Date:  2016-07-20       Impact factor: 12.479

Review 4.  Tumor-targeted nanotherapeutics: overcoming treatment barriers for glioblastoma.

Authors:  Aniket S Wadajkar; Jimena G Dancy; David S Hersh; Pavlos Anastasiadis; Nhan L Tran; Graeme F Woodworth; Jeffrey A Winkles; Anthony J Kim
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-11-04

Review 5.  Targeted delivery of nano-therapeutics for major disorders of the central nervous system.

Authors:  Huile Gao; Zhiqing Pang; Xinguo Jiang
Journal:  Pharm Res       Date:  2013-10       Impact factor: 4.200

6.  Enhanced intracellular delivery and controlled drug release of magnetic PLGA nanoparticles modified with transferrin.

Authors:  Yan-Na Cui; Qing-Xing Xu; Pooya Davoodi; De-Ping Wang; Chi-Hwa Wang
Journal:  Acta Pharmacol Sin       Date:  2017-05-29       Impact factor: 6.150

7.  Nanoparticle formulations that allow for sustained delivery and brain targeting of the neuropeptide oxytocin.

Authors:  Rokon Uz Zaman; Nihal S Mulla; Keegan Braz Gomes; Cherilyn D'Souza; Kevin Sean Murnane; Martin J D'Souza
Journal:  Int J Pharm       Date:  2018-07-19       Impact factor: 5.875

Review 8.  Advances in Targeted Drug Delivery Approaches for the Central Nervous System Tumors: The Inspiration of Nanobiotechnology.

Authors:  Jianing Meng; Vivek Agrahari; Ibrahima Youm
Journal:  J Neuroimmune Pharmacol       Date:  2016-07-23       Impact factor: 4.147

Review 9.  The TWEAK receptor Fn14 is a potential cell surface portal for targeted delivery of glioblastoma therapeutics.

Authors:  J G Perez; N L Tran; M G Rosenblum; C S Schneider; N P Connolly; A J Kim; G F Woodworth; J A Winkles
Journal:  Oncogene       Date:  2015-08-24       Impact factor: 9.867

10.  Decreased non-specific adhesivity, receptor targeted (DART) nanoparticles exhibit improved dispersion, cellular uptake, and tumor retention in invasive gliomas.

Authors:  Aniket S Wadajkar; Jimena G Dancy; Nathan B Roberts; Nina P Connolly; Dudley K Strickland; Jeffrey A Winkles; Graeme F Woodworth; Anthony J Kim
Journal:  J Control Release       Date:  2017-09-05       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.